2. Search Result
Search Result
Results for "

BMDM

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

6

Peptides

2

Inhibitory Antibodies

13

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12815A
    MCC950 sodium
    Maximum Cited Publications
    385 Publications Verification

    CP-456773 sodium; CRID3 sodium salt

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
    MCC950 sodium
  • HY-12815
    MCC950
    Maximum Cited Publications
    385 Publications Verification

    CP-456773; CRID3

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
    MCC950
  • HY-N0379
    D-Mannose

    		Endogenous Metabolite Others Cancer
    D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation .
    D-Mannose
  • HY-173070
    TLR7 agonist 29

    		Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload Inflammation/Immunology Cancer
    TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
    TLR7 agonist 29
  • HY-W615446
    GSTO1-IN-3

    		Glutathione S-transferase Interleukin Related Inflammation/Immunology Cancer
    GSTO1-IN-3 is a potent GSTO1-1 inhibitor with IC50 of 0.11 μM, and shows selectivity over GSTO2-2, GSTA1-1 and GSTP1-1 (IC50 > 100 μM). GSTO1-IN-3 enhances the cytotoxicity of Cisplatin (HY-17394) against human breast cancer cells. GSTO1-IN-3 inhibits IL-1β release in mouse bone marrow-derived macrophage (BMDM) cells. GSTO1-IN-3 attenuates inflammation in mice. GSTO1-IN-3 can be used for breast cancer and inflammation research .
    GSTO1-IN-3
  • HY-163674
    Mincle agonist 1

    		Interleukin Related Inflammation/Immunology
    Mincle agonist 1 (compound 1c) is a Mincle agonist. Mincle agonist 1 can promote IL-1β expression in BMDM cells. Mincle agonist 1 can be used in immune and inflammation related research .
    Mincle agonist 1
  • HY-12815AR
    MCC950 sodium (Standard)

    		NOD-like Receptor (NLR) Inflammation/Immunology
    MCC950 (sodium) (Standard) is the analytical standard of MCC950 (sodium). This product is intended for research and analytical applications. MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
    MCC950 sodium (Standard)
  • HY-12815R
    MCC950 (Standard)

    		NOD-like Receptor (NLR) Inflammation/Immunology
    MCC950 (Standard) is the analytical standard of MCC950. This product is intended for research and analytical applications. MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
    MCC950 (Standard)
  • HY-128776
    Antitumor agent-19

    		TNF Receptor Cancer
    Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC50 values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .
    Antitumor agent-19
  • HY-162848
    IHMT-PI3K-315

    		PI3K Cancer
    IHMT-PI3K-315 (20e) is a potent and selective PI3Kγ/δ inhibitor with IC50 values for PI3Kγ and PI3Kδ of 4.0 and 9.1 nM, respectively. IHMT-PI3K-315 has antitumor activity .
    IHMT-PI3K-315
  • HY-N0379R
    D-Mannose (Standard)

    		Reference Standards Endogenous Metabolite Others
    D-Mannose (Standard) is the analytical standard of D-Mannose. This product is intended for research and analytical applications. D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation .
    D-Mannose (Standard)
  • HY-146594
    NLRP3-IN-8

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-8 (compound 27) is an orally active, directly binding NLRP3 inflammasome inhibitor with an IC50 value of 1.23 μM against IL-1 β. NLRP3-IN-8 has good metabolic stability to liver microsomes (t1/2 = 138.63 min), and has almost no toxicity (against L02: IC50 > 100 μM) .
    NLRP3-IN-8
  • HY-131040
    NLRP3-IN-NBC6

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca 2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .
    NLRP3-IN-NBC6
  • HY-P10384A
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-2 (HY-P10384). SPSB2-iNOS inhibitory cyclic peptide-2 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 TFA is reduction-resistant and oxidatively stable .
    SPSB2-iNOS inhibitory cyclic peptide-2 TFA
  • HY-P10385A
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-3 (HY-P10385). SPSB2-iNOS inhibitory cyclic peptide-3 TFA is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
    SPSB2-iNOS inhibitory cyclic peptide-3 TFA
  • HY-P10384
    SPSB2-iNOS inhibitory cyclic peptide-2

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-2 (Compound CP2) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 21 nM. SPSB2-iNOS inhibitory cyclic peptide-2 is reduction-resistant and oxidatively stable .
    SPSB2-iNOS inhibitory cyclic peptide-2
  • HY-P10385
    SPSB2-iNOS inhibitory cyclic peptide-3

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-3 (Compound CP3) is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 7 nM .
    SPSB2-iNOS inhibitory cyclic peptide-3
  • HY-P990294
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)

    		Transmembrane Glycoprotein STAT Collagen Reactive Oxygen Species (ROS) Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis .
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
  • HY-155108
    OATD-02

    		Arginase Cancer
    OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study .
    OATD-02
  • HY-151252
    NIC-0102

    		Proteasome NOD-like Receptor (NLR) Inflammation/Immunology
    NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
    NIC-0102
  • HY-10109A
    AS-605240 potassium

    		PI3K Akt Inflammation/Immunology
    AS-605240 (potassium) is an orally active PI3Kγ inhibitor (IC50: 8 nM; Ki: 7.8 nM). AS-605240 (potassium) inhibits MCP-1- and CSF1-induced PKB phosphorylation (IC50 values are 0.181 and 0.550 µM, respectively). AS-605240 (potassium) reduces neutrophil recruitment in RANTES (CCL5)- and thioglycolate-induced peritonitis mouse models (EC50 values are 9.1 and 10 mg/kg, respectively). AS-605240 (potassium) ameliorates αCII-IA-induced arthritis in mice .
    AS-605240 potassium
  • HY-149493
    IHMT-PI3K-455

    		PI3K Inflammation/Immunology Cancer
    IHMT-PI3K-455 (Compound 15u) is a potent, selective, orally active PI3Kγ/δ dual inhibitor with IC50s of 7.1 nM and 0.57 nM for PI3Kγ and PI3Kδ, respectively. IHMT-PI3K-455 suppresses the AKT phosphorylation. IHMT-PI3K-455 inhibits tumor growth by recruiting and activating more CD8 + killing T cells.IHMT-PI3K-455 is used in cancer research .
    IHMT-PI3K-455
  • HY-P10383
    SPSB2-iNOS inhibitory cyclic peptide-1

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
    SPSB2-iNOS inhibitory cyclic peptide-1
  • HY-P10383A
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA

    		NO Synthase Infection
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA is the TFA salt form of SPSB2-iNOS inhibitory cyclic peptide-1(HY-P10383). SPSB2-iNOS inhibitory cyclic peptide-1 is an inhibitor for the interaction of SPRY domain and SOCS-box protein 2 (SPSB2) and iNOS, through binding SPSB2 on iNOS site with KD of 4.4 nM. SPSB2-iNOS inhibitory cyclic peptide-1 is resistant to the proteases pepsin, trypsin and α-chymotrypsin. SPSB2-iNOS inhibitory cyclic peptide-1 is stable in human plasma and in oxidative environment .
    SPSB2-iNOS inhibitory cyclic peptide-1 TFA
  • HY-120149
    Inotodiol

    		Toll-like Receptor (TLR) MDM-2/p53 MMP Caspase SOD p38 MAPK NF-κB Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Inotodiol activates p53 signaling pathway, inhibits MMP-2/9, and exhibits antitumor activity in cancer cell HeLa. Inotodiol inhibits the generation of ROS and exhibits antioxidant and neuroprotective effects. Inotodiol inhibits the activation of MAPK and NF-κB signaling pathway, and exhibits anti-inflammatory activity. Inotodiol inhibits TLR-4 mediated TNF-α production (IC50s in BMMC and BMDM is 0.7 μM and 3.0 μM), inhibits the degranulation in mast cell, exhibits anti-allergic activity. Inotodiol is orally active .
    Inotodiol
  • HY-145087A
    NP3-146 sodium

    		NOD-like Receptor (NLR) Interleukin Related Caspase Inflammation/Immunology
    NP3-146 sodium is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 sodium shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 sodium regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 sodium can be used for the research of inflammatory diseases .
    NP3-146 sodium
  • HY-145087
    NP3-146

    NLRP3-IN-5

    		 NOD-like Receptor (NLR) Interleukin Related Caspase Inflammation/Immunology
    NP3-146 is a NLRP3 inflammasome inhibitor through locking the NACHT domain of NLRP3. NP3-146 shows potent inhibitory activity against IL-1β release with an IC50 value of 0.171 μM in LPS (HY-D1056)/Nigericin (HY-127019)-stimulated BMDM cells. NP3-146 regulates the levels of cleaved Caspase-1 and cleaved IL-1β in cell supernatants. NP3-146 can be used for the research of inflammatory diseases .
    NP3-146
  • HY-172134
    NLRP3-IN-70

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis .
    NLRP3-IN-70
  • HY-B1899R
    Taurodeoxycholic acid (Standard)

    		Reference Standards Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Taurodeoxycholic acid (Standard) is the analytical standard of Taurodeoxycholic acid. This product is intended for research and analytical applications. Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholic acid is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholic acid is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholic acid (TDCA) exhibits anti-inflammatory and neuroprotective effects[1][2][3][9][10].
    Taurodeoxycholic acid (Standard)
  • HY-N1939
    Icariside I
    1 Publications Verification

    Icarisid I

    		 Apoptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) STAT CDK Bcl-2 Family Aryl Hydrocarbon Receptor JAK Caspase IFNAR PD-1/PD-L1 Inflammation/Immunology Endocrinology Cancer
    Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape .
    Icariside I
  • HY-N1939R
    Icariside I (Standard)

    Icarisid I (Standard)

    		 Reference Standards Apoptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) STAT CDK Bcl-2 Family Aryl Hydrocarbon Receptor JAK Caspase IFNAR PD-1/PD-L1 Inflammation/Immunology Endocrinology Cancer
    Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape .
    Icariside I (Standard)
  • HY-B1899
    Taurodeoxycholic acid
    5+ Cited Publications

    		 Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholic acid is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholic acid is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholic acid (TDCA) exhibits anti-inflammatory and neuroprotective effects .
    Taurodeoxycholic acid
  • HY-W089835
    Sodium taurodeoxycholate hydrate
    1 Publications Verification

    		 G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Sodium taurodeoxycholate hydrate is a bile salt-related anionic detergent. Sodium taurodeoxycholate hydrate is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Sodium taurodeoxycholate hydrate is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects .
    Sodium taurodeoxycholate hydrate
  • HY-128853S
    Taurodeoxycholate-d6 sodium

    		Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Taurodeoxycholate-d6 sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d6 sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d6 sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d6 (TDCA) exhibits anti-inflammatory and neuroprotective effects .
    Taurodeoxycholate-d6 sodium
  • HY-128853R
    Taurodeoxycholate sodium salt (Standard)

    		Reference Standards Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Taurodeoxycholate sodium salt (Standard) is a bile salt (Standard)-related anionic detergent. Taurodeoxycholate sodium salt (Standard) is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt (Standard) is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects .
    Taurodeoxycholate sodium salt (Standard)
  • HY-N6711
    Equisetin

    		HIV Integrase Bacterial Antibiotic Reactive Oxygen Species (ROS) STAT AMPK 11β-HSD Infection Metabolic Disease
    Equisetin is an N-methylserine-derived acyl tetramic acid, quorum sensing inhibitor (QSI), herbicides and antibiotics. Equisetin specifically inhibits the anionic carriers of substrates in the inner mitochondrial membrane. Equisetin inhibits the activity of HIV-1 integrase, 11β-HSD1, and 2,4-dinitrophenol (Dnp)-stimulated ATPase (IC50 = ~8 nmol per mg of protein). Equisetin exhibits growth inhibition of bacteria, anti-inflammatory, amelioration of lipid-associated disorders, and cytotoxic effects .
    Equisetin
  • HY-128853
    Taurodeoxycholate sodium
    5+ Cited Publications

    		 Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA Neurological Disease Inflammation/Immunology
    Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects .
    Taurodeoxycholate sodium
  • HY-114340
    LEM-14

    		Histone Methyltransferase Apoptosis Cancer
    LEM-14 is a potent and selective NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has very weak activitv against NSD1 and has no activity against NSD3. LEM-14 inhibits fibrotic gene expression in ND but not DIO BMDMs. LEM-14 combined with ionizing radiation (IR) enhances the apoptosis rate and reduces the colony-formation ability of CRC cells. LEM-14 exhibits enhanced anti-tumor efficacy in Balb/c nude mice bearing LoVo cell xenografts when combined with ionizing radiation. LEM-14 has the potential for the research of multiple myeloma and colorectal cancer .
    LEM-14
  • HY-P990820
    Anti-Mouse TIM-4 Antibody (RMT4-53)

    		Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Anti-Mouse TIM-4 Antibody (RMT4-53) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse TIM-4. Anti-Mouse TIM-4 Antibody (RMT4-53) can block T cell immunoglobulin and mucin domain 4 (TIM-4). Anti-Mouse TIM-4 Antibody (RMT4-53) can inhibit the engulfment of apoptotic cells and T cell proliferation. Anti-Mouse TIM-4 Antibody (RMT4-53) can be used for the researches of cancer, immunology and metabolic disease, such as MC38 tumor and graft .
    Anti-Mouse TIM-4 Antibody (RMT4-53)
  • HY-175645
    NLRP3/URAT1-IN-1

    		NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT Metabolic Disease Inflammation/Immunology
    NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .
    NLRP3/URAT1-IN-1
  • HY-171592
    RIPK2-IN-7

    		RIP kinase NOD-like Receptor (NLR) TNF Receptor Inflammation/Immunology
    RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD) .
    RIPK2-IN-7
  • HY-155108B
    OATD-02 hydrochloride
    1 Publications Verification

    		 Arginase Cancer
    OATD-02 hydrochloride is the hydrochloride salt form of OATD-02 (HY-155108). OATD-02 hydrochloride an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and Arginase2. OATD-02 hydrochloride is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 hydrochloride bolishes tumor immunosuppression induced by both arginases. OATD-02 hydrochloride can be used for melanoma study .
    OATD-02 hydrochloride
  • HY-175210
    STING-IN-16

    		STING Interleukin Related IFNAR Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology
    STING-IN-16 is a STING inhibitor with IC50 values of 44 nM (human) and 32 nM (mice) for cellular STING inhibition. STING-IN-16 effectively inhibits the activation of the STING axis in both human and murine cells. STING-IN-16 can restore renal mitochondrial function, suppress reactive oxygen species (ROS) production, and reduce cell apoptosis. STING-IN-16 shows robust anti-inflammatory efiicacy in vivo. STING-IN-16 can be used for the study of autoimmune and autoinflammatory diseases .
    STING-IN-16
  • HY-B2176R
    ATP (Standard)

    Adenosine 5'-triphosphate (Standard)

    		 Reference Standards Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs .
    ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner .
    ATP promotes neutrophil chemotaxis in vitro .
    In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo .
    ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .
    ATP (Standard)
  • HY-W505771
    Seselin

    		Fungal Infection Inflammation/Immunology Cancer
    Seselin is an anticancer, antinociceptive, anti-inflammatory and antifungal agent. Seselin is orally active .
    Seselin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: